Concomitant BRAF Mutation in Hairy Cell Leukemia and Papillary Thyroid Cancer: Case Report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Concomitant BRAF Mutation in Hairy Cell Leukemia and Papillary Thyroid Cancer: Case Report ; volume:12 ; number:3 ; year:2019 ; pages:922-927
Case reports in oncology ; 12, Heft 3 (2019), 922-927
- Urheber
-
Mohamed, Shehab F.
Helmi, Feryal
El-Akiki, Susanna
El Omri, Halima
Nashwan, Abdulqadir
Yassin, Mohamed A.
- DOI
-
10.1159/000504929
- URN
-
urn:nbn:de:101:1-2020011600202096588609
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mohamed, Shehab F.
- Helmi, Feryal
- El-Akiki, Susanna
- El Omri, Halima
- Nashwan, Abdulqadir
- Yassin, Mohamed A.
Ähnliche Objekte (12)
Concomitant uveal melanoma and papillary thyroid carcinoma: a case report
BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer
BRAF Mutation in Papillary Thyroid Microcarcinoma: The Promise of Better Risk Management
Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
High-density microarray expression profiling in conventional papillary thyroid carcinomas with versus without a BRAF mutation
BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma
Prognostic Significance of Various Clinicopathologic Parameters and BRAF V600E Mutation in Papillary Thyroid Microcarcinoma—An Observational Study
Concomitant uveal melanoma and papillary thyroid carcinoma: a case report
BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer
BRAF Mutation in Papillary Thyroid Microcarcinoma: The Promise of Better Risk Management
Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
High-density microarray expression profiling in conventional papillary thyroid carcinomas with versus without a BRAF mutation
BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma
Prognostic Significance of Various Clinicopathologic Parameters and BRAF V600E Mutation in Papillary Thyroid Microcarcinoma—An Observational Study
Concomitant uveal melanoma and papillary thyroid carcinoma: a case report
BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer
BRAF Mutation in Papillary Thyroid Microcarcinoma: The Promise of Better Risk Management
Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
High-density microarray expression profiling in conventional papillary thyroid carcinomas with versus without a BRAF mutation
BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma